Examining the Truvada #BreakThePatent Debate: Gilead Responds  IPWatchdog.com

In July 2012, the FDA first approved Truvada, an AIDS treatment manufactured by Gilead Sciences as a daily pre-exposure prophylactic (PrEP) treatment to …